Detalhe da pesquisa
1.
Bimekizumab versus Adalimumab in Plaque Psoriasis.
N Engl J Med
; 385(2): 130-141, 2021 07 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-33891379
2.
Bimekizumab versus Secukinumab in Plaque Psoriasis.
N Engl J Med
; 385(2): 142-152, 2021 07 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-33891380
3.
Bimekizumab safety in patients with moderate-to-severe plaque psoriasis: pooled data from up to 3â years of treatment in randomized phase III trials.
Br J Dermatol
; 190(4): 477-485, 2024 Mar 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-37950894
4.
Orismilast in moderate-to-severe psoriasis: Efficacy and safety from a 16-week, randomized, double-blinded, placebo-controlled, dose-finding, and phase 2b trial (IASOS).
J Am Acad Dermatol
; 90(3): 494-503, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-37951245
5.
Using Artificial Intelligence as a Melanoma Screening Tool in Self-Referred Patients.
J Cutan Med Surg
; 28(1): 37-43, 2024.
Artigo
em Inglês
| MEDLINE | ID: mdl-38156628
6.
Secukinumab versus guselkumab in the complete resolution of ustekinumab-resistant psoriatic plaques: The ARROW study.
Exp Dermatol
; 32(10): 1834-1847, 2023 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-37272375
7.
Safety of guselkumab treatment for up to 5â years in patients with moderate-to-severe psoriasis: pooled analyses across seven clinical trials with more than 8600 patient-years of exposure.
Br J Dermatol
; 189(1): 42-52, 2023 07 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-37022762
8.
Secukinumab long-term efficacy and safety in psoriasis through to year 5 of treatment: results of a randomized extension of the phase III ERASURE and FIXTURE trials.
Br J Dermatol
; 188(2): 198-207, 2023 02 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-36763857
9.
Bimekizumab maintenance of response through 3â years in patients with moderate-to-severe plaque psoriasis: results from the BE BRIGHT open-label extension trial.
Br J Dermatol
; 188(6): 749-759, 2023 05 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-36967713
10.
Malignancy rates through 5 years of follow-up in patients with moderate-to-severe psoriasis treated with guselkumab: Pooled results from the VOYAGE 1 and VOYAGE 2 trials.
J Am Acad Dermatol
; 89(2): 274-282, 2023 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37019386
11.
Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial.
Lancet
; 397(10273): 487-498, 2021 02 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-33549193
12.
Consistent safety profile with up to 5 years of continuous treatment with guselkumab: Pooled analyses from the phase 3 VOYAGE 1 and VOYAGE 2 trials of patients with moderate-to-severe psoriasis.
J Am Acad Dermatol
; 86(4): 827-834, 2022 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-34798201
13.
Long-term 2-year safety and efficacy of tralokinumab in adults with moderate-to-severe atopic dermatitis: Interim analysis of the ECZTEND open-label extension trial.
J Am Acad Dermatol
; 87(4): 815-824, 2022 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-35863467
14.
Reduced risk of mortality associated with systemic psoriasis treatment in the Psoriasis Longitudinal Assessment and Registry (PSOLAR): A nested case-control analysis.
J Am Acad Dermatol
; 84(1): 60-69, 2021 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-32798580
15.
The use of noninvasive imaging techniques in the diagnosis of melanoma: a prospective diagnostic accuracy study.
J Am Acad Dermatol
; 85(2): 353-359, 2021 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-32289389
16.
Serious Gastrointestinal-Related Adverse Events Among Psoriasis Patients Treated With Guselkumab in VOYAGE 1 and VOYAGE 2.
J Drugs Dermatol
; 20(8): 855-860, 2021 Aug 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34397205
17.
Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial.
Lancet
; 394(10201): 831-839, 2019 09 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-31402114
18.
Ixekizumab treatment and the impact on SF-36: results from three pivotal phase III randomised controlled trials in patients with moderate-to-severe plaque psoriasis.
Qual Life Res
; 29(2): 369-380, 2020 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-31655974
19.
Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis.
N Engl J Med
; 375(4): 345-56, 2016 Jul 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-27299809
20.
Non-Melanoma Skin Cancer Risk Among Patients in the Psoriasis Longitudinal Assessment and Registry (PSOLAR)
J Drugs Dermatol
; 18(10): 1059-1060, 2019 Oct 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31603636